This benefit is due to the dual targeting of DRD2 and alpha 2 adrenergic receptors, which is similar to piribedil, an investigational PD medication that was not included within our final CATNIP network due to a lack of available information. The gene discussed is DRD2; the disease is Parkinson disease.